Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase III study comparing [177Lu]Lu-PSMA-617 vs. standard of care patients with prostate cancer

An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate CancerĀ 

Disease Types: Prostate

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer 

For more information:

https://clinicaltrials.gov/ct2/show/NCT04720157?cond=Lu-PSMA-617&draw=2&rank=6